article thumbnail

Everything You Wanted to Know About Expanded Access but Were Afraid to Ask, Part 1

Bill of Health

Expanded Access is not intended to produce generalizable knowledge; however, it involves reporting of serious adverse events (SAEs) to the entity developing the product (the “sponsor”) and the regulatory agency (the U.S. patients each year. Who qualifies for EA, and how does it work? Full committee review is appropriate.

FDA 237
article thumbnail

A Whole New World for Laboratory Developed Tests – FDA Proposes End to Its Longstanding Policy of Enforcement Discretion

Hall Render

On September 29, 2023, the Food and Drug Administration (“FDA”) announced the issuance of a Notice of Proposed Rulemaking (the “Proposed Rule”) to expand the FDA’s regulatory scope over in vitro diagnostics products (“IVDs”) to specifically address Laboratory Developed Tests (“LDTs”).

FDA 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Modernization of Cosmetics Regulation Act of 2022: What You Need to Know

Healthcare Law Today

Under MoCRA, cosmetic companies will be subject to facility registration and product listing requirements, good manufacturing practices (GMPs), serious adverse event reporting and recordkeeping, and safety substantiation. distribution must register with the FDA no later than one year after the enactment of MoCRA, which is December 29, 2023.

FDA 98
article thumbnail

News from the Consumer Technology Association and Withings Further Demonstrates Private Sector’s Role in the Pandemic and Public Health

Health Populi

This week, announcements from the Consumer Technology Association (CTA) and Withings further bolster the case for the private sector bolstering public health in this pandemic…and future ones to come beyond the Age of the Coronavirus. On 27th July, CTA announced the Association’s launch of the Public Health Tech Initiative.

article thumbnail

FDA Releases Guidances on Transition Plan for Devices Distributed Under Emergency Use Authorization (EUA) or Enforcement Policies During COVID-19

Healthcare Law Blog

On December 22, 2021, the Food and Drug Administration (FDA) published draft guidance documents for manufacturers of devices that were issued Emergency Use Authorizations (EUAs) or were subject to relaxed enforcement policies during the COVID-19 pandemic. Guidance Overview.

article thumbnail

President Biden Signs End-of-Year Legislation Including Telehealth, Medicare & Medicaid, Mental Health, Pandemic Preparedness, and Other Health Care Provisions

C&M Health Law

trillion spending package, which consists of all 12 fiscal year (FY) 2023 appropriations bills and funds the federal government through September 30, 2023, provides additional assistance to Ukraine, and makes numerous health care policy changes. The guidance must address recommendations related to advance digital health technologies (e.g.,

Medicaid 104
article thumbnail

4 Steps for Operationalizing the FDA’s Call To Improve Health Outcomes for All Patients

HIT Consultant

In April, FDA Commissioner Dr. Robert Califf laid out areas of challenge and opportunity when it comes to improving health outcomes, restoring public trust in science, and making the most of our ongoing investments in data analytics and clinical research. Wang, Chief Medical Officer of COTA, Inc.